Celixir plc
Our team of world-class scientists and biotechnology leadership is devoted to discovering breakthrough medicines that change the standard of medical care for patients. Sir Martin Evans, Nobel Laureate, and Ajan Reginald, former Global Head of Emerging Technologies at Roche, originally founded the company under the name Cell Therapy Ltd (CTL) in 2009. CTL was rebranded as Celixir in 2016. Our team of world-class scientists and biotechnology leadership is devoted to discovering breakthrough medicines that change the standard of medical care for patients. We are focussed on developing cell and gene therapies to treat incurable or poorly treated diseases including cancer and heart failure.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Globally (various continents)
About Us
- At Celixir, our values drive all that we do
- Specialist – we are dedicated to delivering medical firsts in specific disease areas where innovation is needed
- World-class – we collaborate with world leaders in science, medicine and business, leveraging their expertise to inform how we make unprecedented impact
- Patient champions - we champion patient needs and ensure they are the first and only motivation for all that we do
- Virtuous – we have a track-record of delivering on our promises and operating with integrity in all of our business interactions
- Access-driven - our mission is to change the lives of patients in need and this commitment is underpinned by tireless efforts to ensure global access to our medicines
- Exceptional - we inspire all employees and partners to reach their full potential and achieve excellence